Chemistry:Selonabant
From HandWiki
Selonabant (INN, USAN; developmental code names ANEB-001, V-24343) is a cannabinoid CB1 receptor antagonist which is under development for the treatment of acute cannabinoid intoxication.[1][2][3] It was also previously being developed to treat obesity, but development for this indication was discontinued.[1] The drug is administered by intravenous infusion.[1] It dramatically reduced the subjective effects of Δ9-tetrahydrocannabinol (THC) in a clinical trial.[3] Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals.[1][2] As of December 2024, it is in phase 2 trials.[1][2]
See also
- Hallucinogen antidote
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Anebulo Pharmaceuticals". 26 December 2024. https://adisinsight.springer.com/drugs/800019731.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Selonabant with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/977f9b08c03c403f83bca0b5e534150c.
- ↑ 3.0 3.1 "CB1 Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial". Clinical Pharmacology and Therapeutics 117 (5): 1427–1436. February 2025. doi:10.1002/cpt.3581. PMID 39898464.
 |  |
